Biblio
“Molecular markers of amnestic mild cognitive impairment among Mexican Americans.”, J Alzheimers Dis, vol. 49, no. 1, pp. 221-8, 2016.
, “Multimodal Magnetic Resonance Imaging in Alzheimer's Disease Patients at Prodromal Stage.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1035-50, 2016.
, “Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1589-1598, 2018.
, “Effects of Physical Exercise on Alzheimer's Disease Biomarkers: A Systematic Review of Intervention Studies.”, J Alzheimers Dis, vol. 61, no. 1, pp. 359-372, 2018.
, “Interaction Between Arteriosclerosis and Amyloid-β on Cognitive Function.”, J Alzheimers Dis, vol. 97, no. 2, pp. 953-961, 2024.
, “Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1097-1105, 2018.
, “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
, “Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.”, J Alzheimers Dis, vol. 61, no. 1, pp. 79-89, 2018.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
, “New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. s1, pp. S51-S63, 2021.
, “Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1485-1492, 2018.
, “Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.”, J Alzheimers Dis, vol. 57, no. 3, pp. 645-665, 2017.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
, “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”, Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
, “The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.”, J Alzheimers Dis, vol. 52, no. 2, pp. 539-59, 2016.
, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
, “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
, “Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.”, J Alzheimers Dis, vol. 50, no. 1, pp. 111-26, 2016.
, “The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
, “Volumetric and shape analysis of the thalamus and striatum in amnestic mild cognitive impairment.”, J Alzheimers Dis, vol. 49, no. 1, pp. 237-49, 2016.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
,